Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

208
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
208
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

70
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
70
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

79
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
79
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

100
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
100
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

88
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
88
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

772
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
772
  1. ホーム
  2. Aprilは,硫酸ヘパランタンパク質に結合することで,動脈硬化症を抑制します.
  1. ホーム
  2. Aprilは,硫酸ヘパランタンパク質に結合することで,動脈硬化症を抑制します.

関連する実験動画

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.4K

APRILは,硫酸ヘパランタンパク質に結合することで,動脈硬化症を抑制します.

Dimitrios Tsiantoulas1, Mahya Eslami2, Georg Obermayer3,4

  • 1Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. dimitris.tsiantoulas@meduniwien.ac.at.

Nature
|August 26, 2021

PubMed で要約を見る

まとめ
この要約は機械生成です。

増殖誘導リガンド (APRIL) は,ヘパラン硫酸プロテオグリカンと結合し,LDLの保持と炎症を減少させ,動脈硬化から保護します. この発見は 心血管疾患の予防に 新たな洞察をもたらします

さらに関連する動画

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.2K
A Novel Stretching Platform for Applications in Cell and Tissue Mechanobiology
16:46

A Novel Stretching Platform for Applications in Cell and Tissue Mechanobiology

Published on: June 3, 2014

11.9K

関連する実験動画

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.4K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.2K
A Novel Stretching Platform for Applications in Cell and Tissue Mechanobiology
16:46

A Novel Stretching Platform for Applications in Cell and Tissue Mechanobiology

Published on: June 3, 2014

11.9K

科学分野:

  • 心血管生物学
  • 免疫学
  • プロテオグリカン 研究

背景:

  • 動脈硬化性心血管疾患は プラーク形成によって引き起こされる 世界の主要な死因です
  • 低密度リポタンパク質 (LDL) が動脈に閉じ込められ,プラークが形成され,炎症を引き起こします.
  • この過程におけるA増殖誘発リガンド (APRIL) の役割は十分に理解されていません.

研究 の 目的:

  • 動脈硬化症の発達におけるAPRILの役割を調査する.
  • APRILが動脈硬化性プラーク形成に影響を与えるメカニズムを解明する.
  • 心血管疾患の治療標的としてAPRILの可能性を調査する.

主な方法:

  • アテロスクレロスのマウスモデルにおけるAPRILの遺伝的消去と抗体媒介による枯渇.
  • 動脈硬化性プラークにおけるLDL保持,マクロファージの蓄積,および死核形成の分析.
  • ヘパラン硫酸プロテオグリカン (HSPG),特にHSPG2との相互作用の調査.
  • 血清非正規APRIL (nc- APRIL) 濃度と患者の心血管死亡率との関連

主要な成果:

  • APRILの欠乏または枯渇は,マウスの動脈硬化症を悪化させた.
  • APRILは,HSPG2と結合し,LDLの保持とマクロファージの蓄積を制限することで,動脈硬化から保護します.
  • ヘパラン硫酸塩欠乏症のHSPG2を持つマウスは,APRILの減少が動脈硬化に効果を示さなかった.
  • 抗APRIL抗体による治療は実験的動脈硬化症を減少させた.
  • 血清のnc- APRIL濃度は,患者の長期的な心血管疾患による死亡率と関連していました.
  • 結論:

    • APRILは,HSPG2経由でLDL保持と炎症を調節することによって,動脈硬化に保護的な役割を果たします.
    • APRILをターゲットに,特にHSPG結合形態は,心血管疾患の新たな治療戦略を提供することができる.
    • 非正規のAPRIL (nc-APRIL) は,心臓血管リスクの潜在的なバイオマーカーとして機能する.